The US Food and Drug Administration (FDA) has granted final approval to Glenmark Pharmaceuticals for its triamcinolone acetonide ointment (0.5 percent), used in treatment of various skin conditions such as eczema, dermatitis, allergies, rash, etc. The approved product is the generic version of Perrigo New York Inc’s triamcinolone acetonide ointment.
According to IMS Health sales data for the 12 months period ending May, the triamcinolone acetonide ointment achieved annual sales of about $ 4.4 million in the US.
Glenmark’s current portfolio consists of 116 products authorised for distribution in the US and 61 ANDAs (abbreviated new drug applications) pending approval with the US FDA.